A13.1. SSJ - 00493- Redacted.pdf

This is a Justification for Sole Source Procurement document for an acquisition under $250,000 from the CDC's Office of Financial Resources for ChromoLogic to provide miRNA sequencing, bioinformatic analyses, and evaluation of signatures of silic-induced fibrosis using proprietary models. The requirement is being processed through the NIOSH/HELD/PPRB office in Morgantown, WV.

The justification cites ChromoLogic's unique capabilities and over 10 years of expertise in leveraging next-generation sequencing to identify circulating miRNA biomarkers that predict pulmonary fibrosis. They are the only vendor with proprietary algorithms being tested in clinical trials for pre-symptomatic detection of radiation-induced pulmonary fibrosis. The document notes that other potential sources were evaluated, including University of Arizona and international research groups, but none had developed the required predictive algorithms for pre-symptomatic detection. The justification is approved through November 27, 2024, with signatures from both the CIO Project Officer and Program Management Officer, though the Contracting Officer's certification remains pending completion.